MacroGenics (MGNX) surged 10% to a 16-month high after B Riley upgraded it to 'Buy' with a $9 target. The firm cited MGNX's strong position in the Antibody-Drug Conjugate space, sparked by Gilead's Tubulus acquisition. This comes after a bullish analyst call highlighted significant upside potential, with the firm projecting gains of up to 140% from current levels.